Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL700049 | 0.90 | AAK1 (0.31) | AAK1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1746812 | 0.88 | HPGDS (0.33) | AAK1CYP3A4CYP2C9 | |
| SCHEMBL2965642 | 0.80 | CYP3A4 (0.43) | CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1746982 | 0.79 | CYP3A4 (0.43) | CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2579880 | 0.77 | CYP3A4 (0.43) | CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16106090 | 0.76 | CYP3A4 (0.38) | AAK1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL700050 | 0.76 | CYP3A4 (0.43) | AAK1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL689892 | 0.76 | NR3C2 (0.36) | — | |
| SCHEMBL12158445 | 0.74 | AAK1 (0.41) | AAK1 | |
| SCHEMBL692400 | 0.74 | HPGDS (0.47) | CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080044380-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044380-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | AAK1 3729/4885CYP1A2 2139/4885CYP3A4 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.